Haemacure Announces Fiscal 2008 Results( HAE:TSX MONTREAL Jan. 21 / Hae...),Health

HAE:TSX

MONTREAL, Jan. 21 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces the results of the fiscal year ended October 31, 2008.

    Operational Highlights

    - Building and commissioning of a manufacturing facility
    - Commencement of plasma fractionation for lead product candidate, an
      all-human fibrin sealant
    - Positive pre-clinical results in new potential indications for fibrin
      sealant in adhesion prevention and skin graft fixation
    - Addition of new board members and strengthening of team

    The most significant achievement of fiscal 2008 was the commencement of
plasma fractionation at Haemacure's facility. Also of major significance were
the positive results of preclinical studies conducted on the efficacy of
Haemacure's proprietary all-human fibrin sealant in the prevention of the
formation of post-surgical adhesions and in skin graft fixation for burn
injuries. These preclinical studies are the first step towards the development
of an expanded portfolio of indications for Haemacure's fibrin sealant based
on its existing general hemostasis formulation. The year was also marked by
significant additions to competencies as Haemacure was successful in
recruiting Mr. Reinaldo M. Diaz and Dr. Thomas J. Lynch as new directors, as
well as strengthening the management, operations and scientific teams.
    "2008 was a year of major accomplishments as we started processing plasma
in our facility to meet our clinical trials timeline", said Mr. Joseph Galli,
Chairman and Chief Executive Officer of Haemacure. "I am excited about the
prospects for 2009 as we enter the clinic and continue to execute on our plan
with a view to becoming a global player offering a next generation, all-human
fibrin sealant", concluded Mr. Galli.

 
'/>"/>
SOURCE  Haemacure Corporation
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 
Related medicine news :

1. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
2. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
3. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
4. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
5. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
6. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
7. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
8. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
9. Haemacure Reports on Financing Progress and Second Quarter Results
10. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
11. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference